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747 bp, respectively (Figure 1B). The sequence of the
more abundant, larger isoform (from now on termed
MyD88L) was found to be identical to the published se-
quence of full-length MyD88 [6, 7]. Sequence analysis
of the smaller isoform showed that it corresponds to a
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Targeted disruption of the MyD88 gene unambigu-
ously showed the importance of MyD88 in IL-1 signaling.Summary
All IL-1 responses (including T cell proliferation and induc-
tion of cytokines and acute phase proteins) were abro-MyD88 is an adaptor protein that is involved in inter-
leukin-1 receptor (IL-1R)- and Toll-like receptor (TLR)- gated in MyD88/ cells, and no NF-B activity was
observed [8]. Activation of NF-B by IL-1 begins withinduced activation of NF-B [1–3]. It is composed of
a C-terminal Toll/IL-1R homology (TIR) domain and the formation of a signaling complex composed of the
IL-1R, IL-1R accessory protein (IL-1RAcP), MyD88, andan N-terminal death domain (DD), which mediate the
interaction of MyD88 with the IL-1R/TLR and the IL-1R- IRAK [1–3]. Interaction with MyD88 triggers IRAK phos-
phorylation [4]. Phosphorylated IRAK leaves the recep-associated kinase (IRAK), respectively. The interaction
of MyD88with IRAK triggers IRAKphosphorylation, which tor complex and associates with TNF receptor-associ-
ated factor 6 (TRAF6) [9], which forms the molecular linkis essential for its activation and downstream signaling
ability [4, 5]. Both domains of MyD88 are separated by to activation of NF-B [10]. A similar function has been
described for MyD88 in LPS-induced signaling; although,a small intermediate domain (ID) of unknown function.
Here, we report the identification of a splice variant the latter also involves a MyD88-independent pathway
[11–13]. Previous reports clearly showed that ectopicof MyD88, termed MyD88S, which encodes for a protein
lacking the ID. MyD88S is mainly expressed in the expression of MyD88 strongly activates NF-B [1–3]. To
test whether MyD88S activates NF-B, HEK293T cellsspleen and can be induced in monocytes upon LPS
treatment. Although MyD88S still binds the IL-1R and were transiently transfected and analyzed for NF-B acti-
vation by reporter gene (Figure 2A) or gel shift assayIRAK, it is defective in its ability to induce IRAK phos-
phorylation and NF-B activation. In contrast, MyD88S (Figure 2A, insert). In contrast to MyD88L, MyD88S over-
expression did not induce DNA binding of NF-B or NF-behaves as a dominant-negative inhibitor of IL-1- and
LPS-, but not TNF-induced, NF-B activation. These B reporter gene activation. These results point to an
important role for the ID of MyD88 in NF-B activationresults implicate the ID of MyD88 in the phosphoryla-
tion of IRAK. Moreover, the regulated expression and and are in agreement with previous findings of Medzhitov
et al. [2], who demonstrated that the DD alone is insuf-antagonistic activity of MyD88S suggest an important
role for alternative splicing of MyD88 in the regulation ficient for NF-B activation. Coexpression of MyD88L
with increasing amounts of MyD88S showed that alreadyof the cellular response to IL-1 and LPS.
low expression levels of MyD88S significantly reduced
the ability of MyD88L to activate NF-B (data not shown).Results and Discussion
In line with these results, MyD88S overexpression almost
completely inhibited IL-1-induced NF-B activation (Fig-The mouse MyD88 gene is organized into five exons and
ure 2A), which is similar to the previously describedfour introns [6]. The first exon (corresponding to amino
effect of overexpression of the TIR domain of MyD88acids 1–109) encodes the DD, the second exon (corre-
[1]. As expected, we did not observe any inhibitory effectsponding to amino acids 110–154) encodes the ID, and
of MyD88S on TNF-induced NF-B activation (Figure 2B).the last three exons (corresponding to amino acids 155–
Because HEK293T cells are unresponsive to LPS, we296) encode the TIR domain (see Figure 1A). RT-PCR
tested the effect of MyD88S on LPS-induced NF-B acti-for MyD88 on RNA isolated from the murine macrophage
vation in Mf4/4 macrophages. Only a partial inhibitorycell line Mf4/4 revealed two cDNA species of 890 and
effect of MyD88S could be observed (Figure 2C), proba-
bly due to the presence of MyD88-independent signal-3 Correspondence: rudi.beyaert@dmb.rug.ac.be
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Figure 1. Identification of a Splice Variant of
MyD88, which Lacks the Intermediate
Domain
(A) A schematic representation of the MyD88L
and MyD88S protein structure, showing the
three different domains and the correspond-
ing exons. Numbers refer to the positioning
of the amino acids.
(B) RT-PCR with MyD88-specific primers on
RNA isolated from Mf4/4 cells. The second
lane shows a control without reverse tran-
scriptase (RT).
(C) PCR analysis on a Balb/c mouse tissue
cDNA panel with MyD88- and -actin-spe-
cific primers.
can function as a negative regulator of IL-1- and LPS- phorylation [4]. This can simply be demonstrated by
coexpression of MyD88 and a mutant version of IRAK,induced NF-B activation.
To find a mechanistic explanation for the dominant- IRAK(T66A), which, in contrast to wild-type IRAK, is
not rapidly degraded by coexpression with MyD88.negative effect of MyD88S in the IL-1-induced signaling
pathway to NF-B, we investigated by coimmunopre- IRAK(T66A) migrates as a series of phosphospecies,
which are converted to a hyperphosphorylation statecipitation whether the splice variant is still present in the
IL-1R/IL-1RAcP complex. MyD88 has previously been (corresponding to the slower migrating species) by
coexpressing MyD88 (Figure 4B, upper panel, and [4]).shown to be recruited as a homodimer to the activated
IL-1R [3]. Both the DD and the TIR domains are required We therefore wished to test whether MyD88S could simi-
larly induce phosphorylation of IRAK(T66A) and foundfor homodimerization [3]. Therefore, we first tested if
MyD88S was still able to form dimers with MyD88L upon that MyD88S did not induce IRAK phosphorylation. Simi-
lar results were obtained when we used an N-terminalexpression in HEK293T cells. The results shown in Fig-
ure 3A demonstrate that E-MyD88S as well as E-MyD88L deletion construct of IRAK(T66A) (IRAK-N(T66A), resi-
dues 1–208, [4]), which, in contrast to full-length IRAK,are coimmunoprecipitated specifically with Flag-MyD88L.
Furthermore, increasing the concentration of E-MyD88S migrates as a single species in unstimulated conditions
(Figure 4B, middle panel). Many studies provided evi-favors the formation of MyD88S-MyD88L heterodimers.
Next, we investigated the binding of MyD88S to the IL-1R/ dence that IRAK undergoes hyperphosphorylation, and
presumably ubiquitination, upon receptor recruitmentIL-1RAcP complex. Coimmunoprecipitation revealed that
MyD88S still binds to the IL-1R/IL-1RAcP complex (Fig- [3, 14, 15]. Phosphorylation of IRAK has previously been
shown to be essential for the interaction of IRAK withure 3B). This is in agreement with previous reports show-
ing that the TIR domain of MyD88, which is intact in TRAF6 [9]. Li et al. [5] demonstrated that deletion mu-
tants of IRAK that are not modified upon IL-1 stimulationMyD88S, is necessary and sufficient for IL-1R binding
[1]. When MyD88S and MyD88L were coexpressed, low are unable to activate NF-B. The inability of MyD88S
to activate NF-B as well as to induce IRAK phosphory-amounts of MyD88S already competed with MyD88L for
binding to the IL-1R/IL-1RAcP complex (Figure 3B). In lation further suggests that both events are correlated.
Although MyD88 is known to be important for IRAKsummary, these results demonstrate that, upon expres-
sion of MyD88S, MyD88S-MyD88L heterodimers are formed phosphorylation [4], the exact mechanism of IRAK phos-
phorylation is still unknown. Reconstitution experimentsand recruited to the IL-1R complex, suggesting that the
dominant-negative effect induced by MyD88S is related of IRAK-deficient cells with kinase-inactive IRAK have
shown that kinase-inactive IRAK still becomes phos-to its inability to bind or to activate downstream signaling
molecules, an obvious candidate being IRAK. phorylated in response to IL-1 [15], demonstrating that
IRAK phosphorylation must be due to another kinase.MyD88 binds IRAK primarily through DD-DD interac-
tions; therefore, it was unlikely that removal of the ID Based on our data, we propose that the ID of MyD88 is
most likely involved in the recruitment and/or activationwould interfere with IRAK binding. Indeed, MyD88S still
binds IRAK (data not shown) and has no effect on its of this additional factor and that MyD88S blocks NF-B
signal transduction via its inability to induce phosphory-recruitment into the IL-1R complex (Figure 4A). Pre-
viously, we have shown that MyD88 triggers IRAK phos- lation of IRAK.
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pression of a splice variant of MyD88, which acts as a
dominant-negative inhibitor of IL-1 and LPS-induced
NF-B activation, suggests an important role for alterna-
tive splicing of MyD88 in the regulation of the cellular
response to IL-1, LPS, and possibly other triggers of
the IL-1R/TLR superfamily. Furthermore, our results also
demonstrate that MyD88 not only functions as a passive
adaptor protein but also plays an active role in the phos-
phorylation and activation of IRAK through its ID.
Supplementary Material
Supplementary Material including the Experimental Procedures is
available at http://images.cellpress.com/supmat/supmatin.htm.
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Figure 3. MyD88S Competes with MyD88L for Dimer Formation and Recruitment to the IL-1R
(A and B) HEK293T cells were transiently transfected with different expression plasmids for epitope-tagged proteins (amounts shown in g on
top of each figure). (A) MyD88L and (B) IL-1R were immunoprecipitated (IP) from cell extracts with anti-Flag antibody, and coimmunoprecipitating
proteins were revealed by Western blotting (WB) with anti-E-tag antibody (upper panel). Immunoprecipitation of Flag-tagged proteins was
confirmed by Western blotting (middle panel). Expression of transfected proteins was confirmed by Western blotting of total lysates (TL) with
anti-E-tag antibody (lower panel).
Figure 4. MyD88S Still Allows IRAK Recruitment to the IL-1R Complex but No Longer Induces IRAK Phosphorylation
(A) HEK293T cells were transiently transfected with expression plasmids for epitope-tagged proteins (amounts shown in g on top of each
figure). Cell extracts were immunoprecipitated (IP) with anti-Flag antibody, and coimmunoprecipitating proteins were revealed by Western
blotting (WB) with an anti-IRAK antibody (upper panel). Immunoprecipitation of Flag-tagged proteins was confirmed by Western blotting
(second panel). Expression of transfected proteins was confirmed by Western blotting of total lysates (TL) with the indicated antibodies (two
lower panels). Upper bands of IRAK represent phosphorylated proteins (IRAK-P), and lower bands represent unphosphorylated IRAK.
(B) HEK293T cells were transiently transfected with expression plasmids for epitope-tagged MyD88 (amounts shown in g on top of the
figure), in combination with either an expression plasmid for IRAK(T66A) or IRAK-N(T66A). Cell lysates were analyzed by Western blotting and
probed with anti-IRAK (upper and middle panel) or anti-E-tag antibody (lower panel).
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Figure 5. Expression of Endogenous MyD88S in LPS-Pretreated
Human Monocytes Is Associated with a Diminished LPS Response
THP-1 cells were either left untreated or were treated with 500
ng/ml LPS for 16 hr, washed three times with serum-free RPMI,
resuspended in fresh culture medium, and restimulated with 500
ng/ml LPS for different time periods.
(A and B) MyD88S and IB- expression levels were analyzed by
Western blotting after 2 hr and 20 min of restimulation with LPS,
respectively.
(C) TNF levels in the supernatant were measured in a TNF bioassay
after 3 hr restimulation with LPS and are expressed as the mean 
standard error of three different samples. No signal means that TNF
levels were below the detection limit of the assay (25 pg/ml).
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